Thank you for your interest in the Cleveland Clinic fellowship program in critical care medicine! The Respiratory Institute of the Cleveland Clinic has trained more than 170 specialists in Pulmonary and Critical Care Medicine since 1965. In 2009, we added a dedicated fellowship in Critical Care Medicine to form future leaders in critical care. We are proud of our fellows, our training environment and culture. Our program mission statement captures the vision of our program, what we aim to accomplish, and how.

Mission Statement

We are committed to training physicians with a passion for clinical care, education, and research to become tomorrow's leaders in pulmonary and critical care medicine through excellence in patient care, scholarship, innovation and leadership.

We will accomplish this by:

  • Providing world-class patient care and unparalleled clinical training
  • Recruiting proactive visionary candidates with a diversity of career goals
  • Promoting individualized mentorship
  • Supporting, protecting, and guiding meaningful educational and research opportunities
  • Innovating in education
  • Teaching and role modeling character traits of effective healers and scholars, including communication, integrity, compassion, and teamwork
  • Embracing quality and safety as a culture

The Cleveland Clinic’s Respiratory Institute is a unique setting for learning all aspects of critical care medicine. With one of the largest medical ICU’s in the U.S., we are internationally recognized as a model for providing critical care resources and managing both common and complex diseases. We are known for our model of developing physician leaders and our commitment to patient-centered care. The Respiratory Institute has also become a leader in healthcare innovation, not only in medicine, but in education. Our Institute’s leadership has supported the education mission of our fellowships through monthly education days, an extensive simulation-based curriculum and a comprehensive, 2-week orientation (Boot camp) with hands-on training in bronchoscopy, ultrasound and bedside ICU procedures.

Our fellows can be involved in a host of research activities from bench and basic science to translational, clinical, quality and educational research projects. We place strong emphasis on mentorship to help fellows achieve their clinical, research, and career goals. Our institute has ample resources to support virtually any kind of research a fellow might choose, with more than 90 staff physicians and researchers and over $11 million in research funding. Further, fellows can work with a host of other institutes across the Cleveland Clinic enterprise to complete their training and research endeavors.

Again, we thank you for your interest in our training program and invite you to discover more about it. If you are considering training as a fellow in critical care medicine, we encourage you to apply to our program through ERAS. We would love to show you in person how we are pursuing the future of critical care education, and how we can help you achieve your professional goals.

Best regards,

Eduardo Mireles-Cabodevila, MD
Program Director

The Respiratory Institute encompasses the Departments of Pulmonary Medicine, Critical Care Medicine and Allergy and Immunology.

The Institute has realized enormous growth in the past several years, tripling the size of its faculty to over 90 physicians and expanding beyond the main campus to seven regional hospitals and 10 free-standing outpatient facilities. Our physicians possess wide-ranging clinical expertise and oversee a number of nationally renowned referral programs serving both common (sarcoidosis, pulmonary vascular disease, lung cancer, interstitial lung disease, asthma, neuromuscular disease) and uncommon (lymphangioleiomyomatosis, hereditary hemorrhagic telangiectasia) disease populations.

Our lung transplant program was second in the nation in annual volume of procedures performed in 2014 and commonly transplants patients turned down by other centers.

Members of our Interventional Pulmonology section perform over 3500 bronchoscopies annually and offer state of the art diagnostic and therapeutic options for patients.

As a testament to our clinical strengths, U.S. News and World Report ranked Cleveland Clinic #3 in the nation for pulmonary services.

Coupled with our clinical initiatives is a thriving research enterprise that encompasses virtually all areas of pulmonary and critical care medicine. Several faculty hold joint appointments in the Lerner Research Institute where they run NIH-funded basic science labs investigating molecular and cellular mechanisms relevant to pulmonary fibrosis, pulmonary hypertension and asthma. Numerous other members of the Respiratory institute have participated in major NIH-sponsored collaborative clinical trials networks including ARDSNet, Idiopathic Pulmonary Fibrosis Clinical Research Network, Prevention and Early Treatment of Acute Lung Injury (PETAL), Long Term Oxygen Treatment Trial (LOTT) for COPD and the Clinical Trials in Organ Transplantation.

Herbert Wiedemann, Institute Chair
Herb Wiedemann

Dr. Wiedemann is Chairman of the Cleveland Clinic Respiratory Institute. He is a graduate of Cornell University College of Medicine and completed residency training in internal medicine at the University of Washington, where he also served as chief medical resident. This was followed by a fellowship in pulmonary and critical care at Yale-New Haven Hospital. Dr. Wiedemann joined the Cleveland Clinic in 1984, assumed the role of Chairman of the Department of Pulmonary, Allergy, and Critical Care in 1991, and with the recent establishment of the Respiratory Institute, became its inaugural Chair. In this role, Dr. Wiedemann has orchestrated the dramatic growth of the Institute faculty, which has more than tripled in size over the past five years and now exceeds 90 members.

Dr. Wiedemann has a long-standing interest in ARDS and has been an active participant in clinical and translational research directly relevant to the treatment of this disorder. Notably, he served as a principal investigator for the NIH-sponsored ARDSnet I and ARDSnet II and was study co-chair of the “Fluids and Catheters Treatment Trial” (FACTT), which demonstrated efficacy of a conservative fluid management strategy in improving lung function and shortening duration of mechanical ventilation and ICU stay. Through his service, frequently as chairman, on the independent monitoring boards of 17 clinical trials related to sepsis and/or ARDS, Dr. Wiedemann gained extensive experience in the design, conduct, and monitoring of clinical trials.

Dr. Wiedemann has authored over 90 original research publications, chapters, and review articles and was the lead editor for three books on acute lung injury. He has served as an ad hoc reviewer for many peer-reviewed publications including New England Journal of Medicine, Annals of Internal Medicine, Chest, European Respiratory Journal, and Journal of Intensive Care Medicine. He is also a former member of the American Board of Internal Medicine Pulmonary Disease Board.

Notable among his recent accomplishments, Dr. Wiederman successfully completed an MBA at Yale while concurrently serving in his role as chair at Cleveland Clinic.

Robert Kotloff, Department Chair-Pulmonary Medicine
Robert Kotloff

Dr. Kotloff is Chairman of the Department of Pulmonary Medicine at the Cleveland Clinic. He has worked in the field of lung transplantation for nearly 25 years and has extensive clinical experience in the evaluation of transplant candidates and in the care of transplant recipients. In addition to his involvement in lung transplantation, Dr. Kotloff has special expertise in the evaluation and management of patients with lymphangioleiomyomatosis (LAM) and other cystic lung diseases. He also maintains an active interest in general pulmonary medicine and, in particular, in evaluating patients with complex pulmonary disorders.

In addition to his clinical activities. Dr. Kotloff has made medical education and scholarship a focus of his career. He has authored over 100 peer-reviewed articles, review articles, and book chapters and has edited or co-edited four books, including the 5th edition of Fishman's Pulmonary Disease and Disorders. He previously directed the Pulmonary and Critical Care Fellowship Training Program at the University of Pennsylvania for 24 years. He served as Chair of the Pulmonary Disease Test Writing Committee of the American Board of Internal Medicine. He also served as Chair of the Transplant Network of the American College of Chest Physicians and as President of the Association of Pulmonary and Critical Care Medicine Program Directors. He was an Associate Editor of the American Journal of Respiratory and Critical Care Medicine from 2010-2014 and currently is a Section Editor for CHEST. He is the 2011 recipient of the American College of Chest Physicians College Medalist Award recognizing “meritorious service in furthering work in chest medicine.” He is also the 2013 recipient of the American Thoracic Society Assembly on Clinical Problems Educator Award given "in recognition of outstanding clinical and educator expertise and significant contribution to clinical education in pulmonary and critical care."

R. Duncan Hite, Department Chair-Critical Care Medicine
R. Duncan Hite

Dr. Hite is the Chairman of the Department of Critical Care at Cleveland Clinic. Prior to his arrvial in 2013, he was Professor of Medicine and Chief of the Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases at Wake Forest University School of Medicine.

In addition to his role as an intensivist, Dr. Hite has actively engaged in clinical and basic science research.  He has served as a principal investigator on numerous clinical trials in critial care including his role as the principal investigator for the Wake Forest clinical center of the prestigious National Institutes of Health (NIH)-sponsored ARDS Network since 2000.  At the Cleveland Clinic, he now serves in a similar role including the role of principal investigator for the NIH Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network, the successor to ARDSNet.  Through its inclusion in PETAL, the Cleveland Clinic has entered its third decade of NIH network participation in ARDS research since the inception of ARDSNet in 1994.   Dr. Hite also holds a joint appointment at the Cleveland Clinic Lerner Research Institute, where he maintains a laboratory focused on mechanisms of acute lung injury, including phospholipase up-regulation, surfactant dysfunction and surfactant replacement therapy.  He has contributed to over 50 original research articles and has written numerous scholarly reviews and book chapters.

Dr. Hite currently serves as the chair of the Program Committee for the ATS Critical Care Assembly.  He serves on the editorial board and as an ad hoc reviewer for multiple respiratory and critical care journals, and has served as chair and member for multiple DSMB and review groups for currently ongoing NIH and industry sponsored clinical trials.   He is the recipient of the Bryant Kendrick Award from the Hospice and Palliative Care Center of Winston-Salem and the Humanitarian Recognition Award from the CHEST Foundation for his work as a board member with the State Employee’s Credit Union Family House while still in Winston-Salem.

Cleveland is a vibrant city situated on the southern shore of Lake Erie, with a population of 400,000 within the city proper and over 2 million in the Cleveland metropolitan area.